Narita M, Feng Y, Makimura M, Hoskins B, Ho I K
Department of Pharmacology and Toxicology, University of Mississippi Medical Center, Jackson 39216-4505.
Eur J Pharmacol. 1994 Dec 27;271(2-3):543-5. doi: 10.1016/0014-2999(94)90817-6.
To investigate the effect of a protein kinase inhibitor, 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (H-7), on the development of tolerance to antinociception induced by morphine (mu-opioid receptor agonist) and butorphanol (mu/delta/kappa-mixed opioid receptor agonist), rats were infused i.c.v. with morphine, butorphanol and H-7 through osmotic minipumps for 3 days. Concomitant infusion of H-7 dose dependently inhibited the development of tolerance to i.c.v. morphine- and butorphanol-induced antinociception. These results suggest that protein kinases may play an important role in the development of opioid tolerance.
为研究蛋白激酶抑制剂1-(5-异喹啉磺酰基)-2-甲基哌嗪(H-7)对吗啡(μ-阿片受体激动剂)和布托啡诺(μ/δ/κ混合阿片受体激动剂)诱导的抗伤害感受耐受性形成的影响,通过渗透微型泵对大鼠进行3天的脑室内吗啡、布托啡诺和H-7输注。同时输注H-7剂量依赖性地抑制了对脑室内吗啡和布托啡诺诱导的抗伤害感受耐受性的形成。这些结果表明蛋白激酶可能在阿片类耐受性形成中起重要作用。